Released May 11, 2021, after the close
10-Q filed May 11, 2021, 41 days after period end · 0001628280-21-009813
Q1 2021 · 10-Q
Revenue$286.00K$286.00K — vs Q1 2020+13.9% vs Q4 2020
Net Income-$22.99M-$22.99M N/M vs Q1 2020N/M vs Q4 2020
EPS Diluted-$0.62-$0.62 N/M vs Q1 2020no prior Q4 2020 on file
Operating Income-$23,130,000N/M
Operating Cash Flow-$23,147,000N/M
Free Cash Flowderived-$24,941,000N/M
Margins · derived
Operating margin-8087.4%
Net margin-8037.1%
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q1 2021 | Q1 2020 |
|---|---|---|
| Revenue | $286.00K | $0.00 |
| Net Income | -$22.99M | -$13.95M |
| EPS Diluted | -$0.62 | -$2.71 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Foghorn Therapeutics Inc. · CIK 1822462 · Engraved from SEC EDGAR